STOCK TITAN

ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

ViiV Healthcare announced 48-week results from the DOLCE study showing that the 2-drug HIV regimen Dovato (dolutegravir/lamivudine) demonstrated comparable efficacy to 3-drug therapy in treating advanced HIV patients. The study involved 230 treatment-naïve individuals with low CD4 counts, with 82% of Dovato patients and 80% of 3-drug therapy patients achieving viral suppression. A post-hoc analysis confirmed Dovato's non-inferiority regardless of baseline viral load. The study population included severely immunosuppressed patients, with 43% having CD4 counts below 100 cells/mL and 69% having high viral loads. Safety profiles were comparable between both treatment groups.

ViiV Healthcare ha annunciato i risultati a 48 settimane dello studio DOLCE, che mostrano come il regime antiretrovirale a 2 farmaci Dovato (dolutegravir/lamivudina) abbia dimostrato un'efficacia comparabile alla terapia a 3 farmaci nel trattamento di pazienti con HIV avanzato. Lo studio ha coinvolto 230 individui naive al trattamento con conteggi di CD4 bassi, con l'82% dei pazienti in trattamento con Dovato e l'80% dei pazienti in terapia a 3 farmaci che hanno raggiunto la soppressione virale. Un'analisi post-hoc ha confermato la non inferiorità di Dovato indipendentemente dal carico virale basale. La popolazione dello studio includeva pazienti gravemente immunosoppressi, con il 43% che presentava conteggi di CD4 inferiori a 100 cellule/mL e il 69% con elevati carichi virali. I profili di sicurezza sono risultati comparabili tra i due gruppi di trattamento.

ViiV Healthcare anunció los resultados de 48 semanas del estudio DOLCE, mostrando que el régimen de VIH de 2 medicamentos Dovato (dolutegravir/lamivudina) demostró una eficacia comparable a la terapia de 3 medicamentos en el tratamiento de pacientes con VIH avanzado. El estudio involucró a 230 individuos naive de tratamiento con bajos recuentos de CD4, con el 82% de los pacientes del grupo Dovato y el 80% de los pacientes del grupo de 3 fármacos alcanzando la supresión viral. Un análisis post-hoc confirmó la no inferioridad de Dovato independientemente de la carga viral basal. La población del estudio incluía pacientes severamente inmunocomprometidos, con el 43% teniendo recuentos de CD4 por debajo de 100 células/mL y el 69% con altas cargas virales. Los perfiles de seguridad fueron comparables entre ambos grupos de tratamiento.

ViiV Healthcare는 DOLCE 연구의 48주 결과를 발표하며 2 약물 HIV 요법 Dovato (돌루테그라비르/라미부딘)가 고급 HIV 환자 치료에서 3 약물 요법과 유사한 효능을 보여주었다고 밝혔습니다. 이 연구에는 낮은 CD4 수치를 가진 230명의 치료를 받지 않은 개인이 포함되었으며, Dovato 환자의 82%와 3 약물 치료 환자의 80%가 바이러스 억제를 달성했습니다. 사후 분석을 통해 기본 바이러스 부하에 관계없이 Dovato의 비열등성이 확인되었습니다. 연구 인구는 심각하게 면역이 억제된 환자들로 구성되었으며, 43%는 CD4 수치가 100 세포/mL 이하였고 69%는 높은 바이러스 부하를 가지고 있었습니다. 두 치료 그룹 간의 안전성 프로필은 유사했습니다.

ViiV Healthcare a annoncé les résultats à 48 semaines de l'étude DOLCE, montrant que le schéma thérapeutique contre le VIH à 2 médicaments Dovato (dolutégravir/lamivudine) a démontré une efficacité comparable à celle de la thérapie à 3 médicaments dans le traitement des patients atteints d'un VIH avancé. L'étude a impliqué 230 individus naïfs de traitement avec de faibles taux de CD4, avec 82 % des patients sous Dovato et 80 % des patients sous la thérapie à 3 médicaments atteignant une suppression virale. Une analyse post-hoc a confirmé la non-infériorité de Dovato quel que soit le niveau de charge virale initial. La population de l'étude a inclus des patients gravement immunodéprimés, avec 43 % ayant des taux de CD4 inférieurs à 100 cellules/mL et 69 % ayant des charges virales élevées. Les profils de sécurité étaient comparables entre les deux groupes de traitement.

ViiV Healthcare hat die Ergebnisse der 48-wöchigen Studie DOLCE veröffentlicht, die zeigen, dass das 2-arzneimittelige HIV-Regime Dovato (Dolutegravir/Lamivudin) eine vergleichbare Wirksamkeit gegenüber der 3-arzneimittigen Therapie bei der Behandlung von fortgeschrittenen HIV-Patienten aufwies. Die Studie umfasste 230 behandlungsnaive Personen mit niedrigen CD4-Werten, wobei 82% der Dovato-Patienten und 80% der Patienten der 3-arzneimittigen Therapie eine virale Suppression erreichten. Eine post-hoc Analyse bestätigte die Nichtunterlegenheit von Dovato, unabhängig von der Grundlage des viralen Lade. Die Studienteilnehmer umfassten schwer immunsupprimierte Patienten, von denen 43% CD4-Werte unter 100 Zellen/mL hatten und 69% hohe Viruslasten aufwiesen. Die Sicherheitsprofile waren zwischen beiden Behandlungsgruppen vergleichbar.

Positive
  • 82% efficacy rate in viral suppression for Dovato, comparable to 80% for 3-drug therapy
  • Demonstrated non-inferior results with a simpler 2-drug regimen vs. traditional 3-drug therapy
  • Effective even in patients with very high viral loads (>500,000 copies/mL)
  • Similar safety profile to existing treatments
Negative
  • Slightly higher discontinuation rate in Dovato group (12.8%) vs. triple therapy (6.8%)

Insights

This clinical trial data demonstrates Dovato's effectiveness as a 2-drug HIV treatment regimen, showing comparable results to traditional 3-drug therapies in treatment-naïve patients with advanced HIV. The key findings reveal 82% virologic success rate for Dovato versus 80% for the 3-drug regimen at 48 weeks, with similar efficacy across different viral load categories.

Particularly noteworthy is the performance in patients with high viral loads (>500,000 copies/mL), where Dovato achieved 74% success versus 67% for triple therapy. The CD4 count improvements (200 cells/mL vs 177 cells/mL) and safety profiles were comparable between both treatments. This data significantly strengthens Dovato's position as a viable alternative to traditional HIV treatments, potentially offering a less burdensome medication regimen without compromising efficacy.

  • Data presented at HIV Glasgow from the DOLCE study demonstrates our commitment to offering effective 2-drug HIV regimens, for people living with advanced HIV
  • A post-hoc analysis shows the 2-drug regimen’s efficacy was comparable to 3-drug therapy in individuals with low baseline CD4 count, regardless of baseline viral load

LONDON--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, sponsored by Fundación Huésped and the Bahiana Foundation of Infectiology, showing the 2-drug regimen Dovato (dolutegravir/lamivudine [DTG/3TC]) achieved similar results to 3-drug therapy in viral suppression in a population of adults with advanced HIV. A post-hoc analysis of the study showed DTG/3TC was non-inferior to 3-drug therapy regardless of the participant’s baseline viral load. These data were presented at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November.

Harmony P. Garges, M.D., Chief Medical Officer, at ViiV Healthcare, said: “We know taking fewer medicines is an important consideration for many in the HIV community, and these new data continue to reinforce the efficacy and safety of Dovato, a 2-drug regimen. The findings from the DOLCE study build on the robust body of evidence supporting its use in treatment-naïve adults living with HIV and shows comparable efficacy to a 3-drug regimen, even in people with low CD4 counts and high viral loads.”

DOLCE is a randomised, open-label, multicentre study assessing the efficacy and safety of DTG/3TC in 230 antiretroviral treatment (ART)-naïve people with advanced HIV (low CD4 counts [≤200 cells/mL]).1 In the clinical trial, participants were randomised in a 2:1 ratio to receive DTG/3TC (n=152) or DTG+TDF/XTC (n=77). The baseline characteristics of the participants were similar between the two treatment groups and represented a population of people with severe immunosuppression – 43% of participants having baseline CD4 counts less than 100 cells/mL, 69% having baseline viral load (VL) greater than 100,000 copies (c)/mL, and 23% having a very high baseline VL, greater than 500,000 copies (c)/mL.

The primary endpoint of the study was the proportion of subjects with VL <50 copies/ml at week 48. At week 48 comparable efficacy was observed, with 82% of individuals in the DTG/3TC group and 80% in the 3-drug regimen group achieving a VL<50. Furthermore, a post-hoc analysis showed that Dovato was non-inferior to the 3-drug regimen in achieving a VL<50.

Prof. Pedro Cahn, Scientific Director of Fundación Huésped study investigator of the DOLCE study, said: “It’s encouraging to see additional new data that continue to support the efficacy and safety of 2-drug regimens compared to traditional 3-drug regimens. The results from DOLCE provide healthcare providers with further confidence in prescribing DTG/3TC and are important findings for people living with HIV taking medicines to suppress their virus.”

A post-hoc analysis reported that DTG/3TC was non-inferior to 3-drug therapy (adjusted risk difference of 2.0%, 95% CI -8.6; 12.8%).1 The study also showed that secondary efficacy measures of viral load decline, time to viral suppression, and CD4 recovery were similar between arms. Efficacy by baseline viral load categories was similar across both arms, including those with baseline viral load greater than 500,000 copies with 74% in the DTG/3TC arm, and 67% in the DTG+TDF/XTC arm achieving virologic success. The change in median CD4 count from baseline to Week 48 showed an increase of 200 cells/mL in the DTG/3TC arm and an increase of 177 cells/mL in the triple therapy arm.

Safety through Week 48 was comparable across both arms and consistent with known safety profiles and showed similar rates of serious adverse events (SAEs) and immune reconstitution inflammatory syndrome across arms. The rate of discontinuation in both arms was also similar (DTG/3TC = 12.8%; DTG+TDF/XTC = 6.8%).

About DOLCE

The DOLCE (NCT04880395) randomised clinical trial is a phase IV, open-label, multicentre clinical trial assessing the efficacy of DTG/3TC for the treatment of HIV-1 in treatment-naïve adults 18 years or older with CD4+ T-cell count ≤200 c/mm3 and HIV-1 RNA >1,000 copies/mL with no known ART-resistance or HBV co-infection, conducted in 11 sites across Argentina and Brazil. The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 c/mL at Week 48 (FDA snapshot for ITT-E population) and secondary outcomes included, among others, efficacy, resistance, safety, and tolerability.

About Dovato

Dovato is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato.

Dovato is approved in the US, Europe, Japan, Australia, and other countries worldwide.

Please consult the full Summary of Product Characteristics for all the safety information: Dovato 50 mg/300 mg film-coated tablets.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

About Fundación Huésped

Fundación Huésped is an Argentine organisation with a regional reach that has been working in public health since 1989, aiming to ensure the right to health and the control of diseases are guaranteed. Our comprehensive approach includes the development of research, practical solutions, and communications related to public health policies in our country and the region. Our mission is to conduct scientific research and implement preventive actions and rights-promotion initiatives to ensure access to healthcare and reduce the impact of diseases, with a focus on HIV/AIDS, viral hepatitis, vaccine-preventable diseases, and other transmissible diseases, as well as sexual and reproductive health.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024.

Registered in England & Wales:

 

GSK plc

ViiV Healthcare Limited

No. 3888792

No. 06876960

 

Registered Office:

 

79 New Oxford Street

ViiV Healthcare Limited

London

GSK Medicines Research Centre

WC1A 1DG

Gunnels Wood Road, Stevenage

 

United Kingdom

 

SG1 2NY

References
1M. I. Figueroa, et al. Comparable efficacy and safety of dolutegravir / lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study. Presented at HIV Glasgow 2024, 10 – 13 November, Glasgow, Scotland.

For media and investors only

ViiV Healthcare enquiries:

Media enquiries:

Rachel Jaikaran +44 (0) 78 2352 3755 (London)

Melinda Stubbee +1 919 491 0831 (North Carolina)

Fundación Huésped enquiries:

Media:

Guadalupe Di Palma +54 9 11 3083 9726 (Argentina)

GSK enquiries:

Media:

Tim Foley +44 (0) 20 8047 5502 (London)

Sarah Clements +44 (0) 20 8047 5502 (London)

Kathleen Quinn +1 202 603 5003 (Washington DC)

Lyndsay Meyer +1 202 302 4595 (Washington DC)

Alison Hunt +1 540 742 3391 (Washington DC)

Investor Relations:

James Dodwell +44 (0) 20 8047 2406 (London)

Mick Readey +44 (0) 7990 339653 (London)

Camilla Campbell +44 (0) 7803 050238 (London)

Steph Mountifield +44 (0) 7796 707505 (London)

Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Frannie DeFranco +1 215 751 4855 (Philadelphia)

Source: ViiV Healthcare

FAQ

What were the efficacy rates of Dovato in the DOLCE study for HIV treatment?

The DOLCE study showed 82% of patients receiving Dovato achieved viral suppression at week 48, compared to 80% in the 3-drug therapy group.

How did Dovato perform in patients with high viral loads?

Dovato showed 74% efficacy in patients with viral loads >500,000 copies/mL, compared to 67% in the triple therapy arm, demonstrating effectiveness even in cases of high viral load.

What was the CD4 count improvement with Dovato in the DOLCE study?

Patients treated with Dovato showed a median CD4 count increase of 200 cells/mL at Week 48, compared to 177 cells/mL in the triple therapy arm.

Pfizer Inc.

NYSE:PFE

PFE Rankings

PFE Latest News

PFE Stock Data

140.60B
5.66B
0.05%
67.77%
1.09%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW YORK